Related Experiment Video
Updated: Aug 30, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria
Peter Schneider1, Stephen Hawser, Khalid Islam
1Arpida Ltd, Dammstrasse 36, CH-4142, Muenchenstein, Switzerland. pschneider@arpida.ch
Abstract:
Iclaprim, a new selective dihydrofolate inhibitor was synthesized based on rational drug design. Iclaprim's interaction with a resistant Staphylococcus aureus dihydrofolate reductase (DHFR) is outlined in comparison to trimethoprim (TMP). This compound is active against methicillin, TMP and vancomycin resistant strains. Arpida Ltd. is developing Iclaprim for serious hospital infections from Gram-positive pathogens and respiratory tract infections.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Bacterial Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Gram-positive Cell Wall Synthesis
Anthelminthic Agents

